WUH-LIANG HWUYIN-HSIU CHIEN2020-12-162020-12-1620202409-515Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85081665805&doi=10.3390%2fijns6010005&partnerID=40&md5=f93b3fad7c29f773c91052c4e0d5cc19https://scholars.lib.ntu.edu.tw/handle/123456789/525783[SDGs]SDG3alglucosidase alfa; alpha glucosidase; glucosidase; lysosome enzyme; cardiac muscle; disease severity; Editorial; Food and Drug Administration; glycogen storage disease type 2; heart failure; human; immunomodulation; motor development; muscle biopsy; muscle injury; muscle weakness; newborn screening; outcome assessment; phase 3 clinical trial (topic); respiratory failure; respiratory tract infection; sensitivity and specificityeditorial10.3390/ijns60100052-s2.0-85081665805